Endothelial-Mesenchymal Transition in COVID-19 lung lesions.
Pathol Res Pract
; 221: 153419, 2021 May.
Article
in English
| MEDLINE | ID: covidwho-1157674
ABSTRACT
Sars-Cov-2 infection is still a healthcare emergency and acute respiratory distress failure with Diffuse Alveolar Damage (DAD) features is the main causes of patients' death. Pathogenic mechanisms of the disease are not clear yet, but new insights are necessary to improve therapeutic management, to prevent fatal irreversible multi-organ damage and to adequately follow up those patients who survive. Here we investigated, by histochemistry and immunohistochemistry, a wide number of mapped lung specimens taken from whole body autopsies of 7 patients dead of COVID-19 disease. Our data confirm morphological data of other authors, and enlarge recent reports of the literature suggesting that Endothelial-Mesenchymal Transition might be central to COVID-19 lung fibrosing lesions. Furthermore, based upon recent acquisition of new roles in immunity and vascular pathology of the CD31 molecule, we hypothesize that this molecule might be important in the development and treatment of COVID-19 pulmonary lesions. These preliminary findings need further investigations to shed light on the complexity of Sars-Cov-2 disease.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Epithelial-Mesenchymal Transition
/
COVID-19
/
Lung Diseases
Type of study:
Cohort study
/
Prognostic study
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Pathol Res Pract
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS